Skip to main content
Premium Trial:

Request an Annual Quote

New Fundings Hold Steady From May to June

NEW YORK, July 2 – The number of new funding deals did not change significantly from May to June, a report released Monday by Facts Online said.

During the month of June the number of fundings was at 306, nearly identical to 309 in May. In April 325 companies received funding.

“It’s encouraging that it’s stable in light of all the gnashing of teeth about the downturn in the economy,” said Harry Henry, chief operating officer of Facts Online, which tracks funding trends. “It’s not as robust as last year [at this time], but we’re not in a downward spiral.”

The survey includes all funding deals stemming from venture capital, investments by other companies, initial public offerings, private placements, new bond issues, and increases in lines of credit. 

Fundings for companies in the pharmaceutical, biotech, and health devices category represented 15 percent of the total deals. Software companies dominated the fundings, representing 32.9 percent of the deals.

Of the companies funded, 79.4 percent were privately owned. Of the public companies, the highest percentage, 14.4 percent, were listed on Nasdaq.

The Scan

Booster for At-Risk

The New York Times reports that the US Food and Drug Administration has authorized a third dose of the Pfizer-BioNTech SARS-CoV-2 vaccine for people over 65 or at increased risk.

Preprints OK to Mention Again

Nature News reports the Australian Research Council has changed its new policy and now allows preprints to be cited in grant applications.

Hundreds of Millions More to Share

The US plans to purchase and donate 500 million additional SARS-CoV-2 vaccine doses, according to the Washington Post.

Nature Papers Examine Molecular Program Differences Influencing Neural Cells, Population History of Polynesia

In Nature this week: changes in molecular program during embryonic development leads to different neural cell types, and more.